CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY – Get Free Report) was the target of a large decline in short interest during the month of October. As of October 30th, there was short interest totaling 641 shares, a decline of 40.0% from the October 15th total of 1,068 shares. Based on an average daily volume of 26,431 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are short sold.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. Jefferies Financial Group downgraded CochLear from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Canaccord Genuity Group downgraded CochLear from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 18th. Five research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $117.00.
Check Out Our Latest Analysis on CochLear
CochLear Trading Down 1.4%
About CochLear
Cochlear Limited is an Australian medical-device company that develops and supplies implantable hearing solutions for people with significant hearing loss. Its products are designed to help users access sound when conventional hearing aids may not provide sufficient benefit. The company’s offerings include cochlear implant systems and sound processors, as well as bone-conduction hearing implants and related accessories. It also provides services and support for recipients, families, and hearing-health professionals.
See Also
- Five stocks we like better than CochLear
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.
